Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 25;24(12):2093–2106. doi: 10.1093/neuonc/noac107

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Fig. 2 — Decitabine decreases methylation and increases expression of both cancer testis antigens and neoantigens in primary GBM cell lines. (A-C) MA plots comparing expression of (A) all genes, (B) cancer testis antigens and (C) neoantigens in primary GBM cell lines with and without DAC treatment. (D,E) Volcano plots showing differential methylation of (D) cancer testis antigens and (E) neoantigens following DAC treatment. Colored dots represent individual genes with significantly (P < .05) altered expression following DAC treatment, direction of arrow signifies direction of change. (F,G) violin plots showing methylation levels of (F) cancer testis antigens and (G) neoantigens of primary cell lines with and without DAC treatment as well as primary tumor samples. Data shown are from 3 biological replicates. Tumor—primary tumor sample; control—primary tumor cell lines not treated with DAC; DAC—primary tumor cell lines treated with DAC. * P < .05, ** P < .01, *** P < .001, **** P < .0001.